drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous, fully human anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy that targets and depletes CD19+ B-lineage cells to reduce pathogenic autoantibodies and B cell–driven inflammation.
nci_thesaurus_concept_id
C210038
nci_thesaurus_preferred_term
Autologous Anti-CD19 CAR-CD8alpha-CD28-CD3zeta T Cells KYV 101
nci_thesaurus_definition
A preparation of autologous CD4- and CD8-positive T-cells that are transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) consisting of a human single chain variable fragment (scFv) of anti-CD19 and fused to the hinge and transmembrane domains of CD8alpha co-receptor, the cytoplasmic costimulatory domain of human CD28, and the T-cell antigen receptor complex zeta chain (CD3-zeta), with potential immunostimulating activity. Upon transfusion, autologous anti-CD19 CAR-CD8alpha-CD28-CD3zeta T cells KYV 101 recognize and induce selective toxicity and lysis in CD19-expressing B-cells. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies and in certain B-cell-driven autoimmune diseases.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a fully human anti‑CD19 CAR (CD8α hinge/transmembrane, CD28 costimulatory, CD3ζ signaling). After infusion, the CAR-T cells recognize CD19 on B-lineage cells, become activated, expand, and mediate cytolytic killing, depleting CD19+ B cells to reduce pathogenic autoantibodies and B cell–driven inflammation.
drug_name
KYV-101
nct_id_drug_ref
NCT05938725